A Case of Multiple Pyogenic Granulomas Induced by Ramucirumab
Author:
Affiliation:
1. Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2. Department of Allergy and Respiratory Medicine, Okayama University Hospital
Publisher
Western Japan Division of JDA
Subject
Dermatology
Link
https://www.jstage.jst.go.jp/article/nishinihonhifu/84/4/84_337/_pdf
Reference18 articles.
1. 1) 化学療法既治療の切除不能な進行・最初の非小細胞肺癌<ドセタキセル併用投与>抗悪性腫瘍剤 ヒト型抗 VEGFR-2 モノクローナル抗体 サイラムザ®点滴静注液 適正使用ガイド.
2. 2) Garon EB, Ciuleanu TE, Arrieta O et al : Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet, 2014 ; 384 : 665-673.
3. 3) Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G : Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med, 2014 ; 2 : 123.
4. 4) Watanabe R, Nakano E, Kawazoe A et al : Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab. J Dermatol, 2019 ; 46 : 178-180.
5. 5) Kosumi H, Nishie W, Sugai T et al : Ramucirumab-induced Multiple Haemangiomas of the Skin : Two Case Reports. Acta Derm Venereol, 2018 ; 98 : 454-455.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Docetaxel/nivolumab/ramucirumab;Reactions Weekly;2023-04-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3